SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

SIMPLAAFY Study Meets Primary Endpoints for WATCHMAN FLX Pro Device

Both post-implant monotherapies in the trial achieved non-inferiority compared with dual anti-platelet therapy.

BSX

Related stories